Physician profile
Keri E Dillon
NPI 1093196909
$2,241.28
in general payments reported to CMS, 2019-2025
28 companies · $291 in 2025
The $291 reported for 2025 was more than what a typical Primary Care provider received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $503 · 2022: $307 · 2023: $633 · 2024: $507 · 2025: $291.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,431.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,431.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $475.79 | 2021-2025 | |
| Lilly USA, LLC | $296.85 | 2021-2024 | Mounjaro, Emgality, Jardiance |
| Novo Nordisk INC | $293.52 | 2021-2024 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $273.95 | 2021-2025 | |
| Aimmune Therapeutics, INC. | $112.05 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $110.99 | 2022-2025 | Airsupra, Bevespi Aerosphere |
| Nestle Healthcare Nutrition INC. | $88.02 | 2021-2023 | |
| Medtronic, INC. | $65.51 | 2023 | Venaseal, Minimed 780g |
| Amgen INC. | $61.44 | 2023-2024 | Evenity, Prolia |
| Procept Biorobotics Corporation | $60.25 | 2024 | Aquabeam System |
| Exact Sciences Corporation | $46.05 | 2024-2025 | Cologuard Collection Kit |
| Grifols USA, LLC | $40.60 | 2023 | Prolastin-C Liquid |
| Kowa Pharmaceuticals America, INC. | $33.54 | 2021 | |
| Esperion Therapeutics, INC. | $29.34 | 2021 | |
| Mylan Specialty L.P. | $23.59 | 2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $21.15 | 2022 | |
| Glaxosmithkline, LLC. | $20.99 | 2021 | |
| Boston Scientific Corporation | $20.80 | 2024 | Watchman Flx |
| Abbott Laboratories | $20.74 | 2024 | Freestyle Libre 3 |
| Xeris Pharmaceuticals, INC. | $18.79 | 2023 | Gvoke Hypopen |
| Sanofi Pasteur INC. | $17.60 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.00 | 2023 | |
| Ultragenyx Pharmaceutical INC. | $16.61 | 2022 | |
| Philips North America LLC | $16.32 | 2024 | (5050) Extended Holter |
| Bayer Healthcare Pharmaceuticals INC. | $15.78 | 2024 | |
| Axsome Therapeutics, INC. | $15.74 | 2025 | Auvelity |
| Eisai INC. | $15.57 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $12.70 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keri Dillon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.